Cassava Sciences (NASDAQ:SAVA – Get Free Report) announced its earnings results on Monday. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.42, Zacks reports.
Cassava Sciences Stock Down 7.7 %
SAVA stock opened at $2.40 on Monday. Cassava Sciences has a twelve month low of $2.23 and a twelve month high of $42.20. The company has a market cap of $115.46 million, a price-to-earnings ratio of -1.74 and a beta of -0.95. The business has a 50 day moving average price of $2.53 and a two-hundred day moving average price of $15.48.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright cut shares of Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 price target on the stock. in a research report on Tuesday, November 26th.
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
- Five stocks we like better than Cassava Sciences
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 4 Blockchain Stocks That Aren’t Coinbase
- How to Read Stock Charts for Beginners
- These 3 Tech Stocks Are Gaining Steam After NVIDIA’s Report
- How to buy stock: A step-by-step guide for beginners
- These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
